Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Tien Dam¹, Adam L Boxer², Lawrence I Golbe³, Günter U Höglinger^{4

5

6}, Huw R Morris⁷, Irene Litvan⁸, Anthony E Lang⁹, Jean-Christophe Corvol¹⁰, Ikuko Aiba¹¹, Michael Grundman^{8

12}, Lili Yang¹³, Beth Tidemann-Miller¹³, Joseph Kupferman¹³, Kristine Harper¹³, Kubra Kamisoglu¹³, Michael J Wald¹³, Danielle L Graham¹³, Liz Gedney¹³, John O'Gorman¹³, Samantha Budd Haeberlein¹³; PASSPORT Study Group

Collaborators, Affiliations

Collaborators

PASSPORT Study Group:
Ikuko Aiba, Angelo Antonini, Diana Apetauerova, Jean-Philippe Azulay, Ernest Balaguer Martinez, Jee Bang, Paolo Barone, Matthew Barrett, Danny Bega, Daniela Berg, Koldo Berganzo Corrales, Yvette Bordelon, Adam L Boxer, Moritz Brandt, Norbert Brueggemann, Giovanni Castelnovo, Roberto Ceravolo, Rosalind Chuang, Sun Ju Chung, Alistair Church, Jean-Christophe Corvol, Paola Cudia, Marian Dale, Luc Defebvre, Sophie Drapier, Erika D Driver-Dunckley, Georg Ebersbach, Karla M Eggert, Aaron Ellenbogen, Alexandre Eusebio, Andrew H Evans, Natalia Fedorova, Elizabeth Finger, Alexandra Foubert-Samier, Boyd Ghosh, Lawrence Golbe, Francisco Grandas Perez, Murray Grossman, Deborah Hall, Kyoko Hamada, Kazuko Hasegawa, Guenter Hoeglinger, Lawrence Honig, David Houghton, Xuemei Huang, Stuart Isaacson, SeongBeom Koh, Jaime Kulisevsky Bojarski, Anthony E Lang, Peter Nigel Leigh, Irene Litvan, Juan Jose Lopez Lozano, Jose Luis Lopez-Sendon Moreno, Albert Christian Ludolph, Ma Rosario Luquin Piudo, Irene Martinez Torres, Nikolaus McFarland, Wassilios Meissner, Tiago Mestre, Pablo Mir Rivera, Eric Molho, Britt Mollenhauer, Huw R Morris, Miho Murata, Tomokazu Obi, Fabienne Ory Magne, Padraig O'Suilleabhain, Rajesh Pahwa, Alexander Pantelyat, Nicola Pavese, Dmitry Pokhabov, Johannes Prudlo, Federico Rodriguez-Porcel, James Rowe, Joseph Savitt, Alfons Schnitzler, Joerg B Schulz, Klaus Seppi, Binit Shah, Holly Shill, David Shprecher, Maria Stamelou, Malcolm Steiger, Yuji Takahashi, Hiroshi Takigawa, Carmela Tartaglia, Lars Toenges, Daniel Truong, Winona Tse, Paul Tuite, Dieter Volc, Anne-Marie A Wills, Dirk Woitalla, Tao Xie, Tatsuhiko Yuasa, Sarah Elizabeth Zauber, Theresa Zesiewicz

Affiliations

¹ Biogen, Cambridge, MA, USA. tien.dam@biogen.com.
² Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
³ Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
⁴ Department of Neurology, Technische Universität München, Munich, Germany.
⁵ German Center for Neurodegenerative Diseases, Munich, Germany.
⁶ Department of Neurology, Hanover Medical School, Hanover, Germany.
⁷ National Hospital for Neurology and Neurosurgery, London, UK.
⁸ University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.
⁹ Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
¹⁰ Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.
¹¹ Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
¹² Global R&D Partners, LLC, San Diego, CA, USA.
¹³ Biogen, Cambridge, MA, USA.

PMID: 36253611
DOI: 10.1038/s41591-022-02076-8

Free article

Published Erratum

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Tien Dam et al. Nat Med. 2023 Nov.

Free article

. 2023 Nov;29(11):2955-2956.

doi: 10.1038/s41591-022-02076-8.

Authors

Collaborators

PASSPORT Study Group:
Ikuko Aiba, Angelo Antonini, Diana Apetauerova, Jean-Philippe Azulay, Ernest Balaguer Martinez, Jee Bang, Paolo Barone, Matthew Barrett, Danny Bega, Daniela Berg, Koldo Berganzo Corrales, Yvette Bordelon, Adam L Boxer, Moritz Brandt, Norbert Brueggemann, Giovanni Castelnovo, Roberto Ceravolo, Rosalind Chuang, Sun Ju Chung, Alistair Church, Jean-Christophe Corvol, Paola Cudia, Marian Dale, Luc Defebvre, Sophie Drapier, Erika D Driver-Dunckley, Georg Ebersbach, Karla M Eggert, Aaron Ellenbogen, Alexandre Eusebio, Andrew H Evans, Natalia Fedorova, Elizabeth Finger, Alexandra Foubert-Samier, Boyd Ghosh, Lawrence Golbe, Francisco Grandas Perez, Murray Grossman, Deborah Hall, Kyoko Hamada, Kazuko Hasegawa, Guenter Hoeglinger, Lawrence Honig, David Houghton, Xuemei Huang, Stuart Isaacson, SeongBeom Koh, Jaime Kulisevsky Bojarski, Anthony E Lang, Peter Nigel Leigh, Irene Litvan, Juan Jose Lopez Lozano, Jose Luis Lopez-Sendon Moreno, Albert Christian Ludolph, Ma Rosario Luquin Piudo, Irene Martinez Torres, Nikolaus McFarland, Wassilios Meissner, Tiago Mestre, Pablo Mir Rivera, Eric Molho, Britt Mollenhauer, Huw R Morris, Miho Murata, Tomokazu Obi, Fabienne Ory Magne, Padraig O'Suilleabhain, Rajesh Pahwa, Alexander Pantelyat, Nicola Pavese, Dmitry Pokhabov, Johannes Prudlo, Federico Rodriguez-Porcel, James Rowe, Joseph Savitt, Alfons Schnitzler, Joerg B Schulz, Klaus Seppi, Binit Shah, Holly Shill, David Shprecher, Maria Stamelou, Malcolm Steiger, Yuji Takahashi, Hiroshi Takigawa, Carmela Tartaglia, Lars Toenges, Daniel Truong, Winona Tse, Paul Tuite, Dieter Volc, Anne-Marie A Wills, Dirk Woitalla, Tao Xie, Tatsuhiko Yuasa, Sarah Elizabeth Zauber, Theresa Zesiewicz

Affiliations

¹ Biogen, Cambridge, MA, USA. tien.dam@biogen.com.
² Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
³ Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
⁴ Department of Neurology, Technische Universität München, Munich, Germany.
⁵ German Center for Neurodegenerative Diseases, Munich, Germany.
⁶ Department of Neurology, Hanover Medical School, Hanover, Germany.
⁷ National Hospital for Neurology and Neurosurgery, London, UK.
⁸ University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.
⁹ Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
¹⁰ Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.
¹¹ Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
¹² Global R&D Partners, LLC, San Diego, CA, USA.
¹³ Biogen, Cambridge, MA, USA.

PMID: 36253611
DOI: 10.1038/s41591-022-02076-8

No abstract available

PubMed Disclaimer

Erratum for

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385707 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Andalusian Health Repository - access to free full text
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Collaborators

Affiliations

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Authors

Collaborators

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources